ArticleActa epileptologica2026
Phenobarbital monotherapy for convulsive seizures in rural Northwest China: a 12-year longitudinal study.
Article in Acta epileptologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study was conducted as part of the China Epilepsy Prevention and Control Management Project. The research aimed to investigate the efficacy of phenobarbital (PB) and prognostic factors for convulsive seizures in rural areas of northwest China.
methodsPatients with convulsive seizures were recruited from seven rural regions in Shaanxi Province, Northwest China, between January 2011 and December 2022. Patients over 6 years old and had at least one convulsive seizure at baseline (within 12 months prior to screening) were included. They were prescribed PB monotherapy according to a standardized protocol. During follow-up, the efficacy of PB was annually estimated by the reduction in seizure frequency. At the five-year follow-up, prognosis was assessed by the proportion of patients who achieved three consecutive seizure-free years.
resultsA total of 1001 patients (mean age 40.9 years, 56.8% male) were included. The median follow-up duration was 5 years (interquartile range [IQR], 3-8; maximum 12 years). The median baseline seizure frequency was 5 seizures (IQR 3-12) per year. The proportion of patients achieving a 50% reduction in seizure frequency was 62.1% (622/1001) in the first year and 93.0% (133/143) by the tenth year, respectively. In total, 528 individuals achieved 3-year remission (3YR), 473 participants did not achieve 3YR. Patients who achieved 3YR demonstrated significantly higher rates of seizure freedom within the initial 24-month treatment period compared to non-3YR patients (89% vs 37%, respectively, P < 0.001). Multivariate analysis revealed that patients with a baseline seizure frequency exceeding 10 seizures per year had a significantly higher risk of failure to achieve 3YR (OR 2.13, 95%CI 1.63-2.78, P < 0.001). Adverse effects of PB were mostly mild, with 490 patients (48.9%) recording adverse reactions one month after prescription and decreased to 238 patients (23.8%) at their last visit (median follow-up 4 [IQR 2-7] years).
conclusionsOur study demonstrated that convulsive seizures could be effectively controlled with PB monotherapy with mild adverse effects in rural areas in Northwest China. Early treatment response, particularly seizure freedom within the first two years, is a strong indicator of long-term remission. High baseline seizure frequency is an independent risk factor for poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.